MX344222B - Una formulacion novedosa de naproxeno. - Google Patents
Una formulacion novedosa de naproxeno.Info
- Publication number
- MX344222B MX344222B MX2011011220A MX2011011220A MX344222B MX 344222 B MX344222 B MX 344222B MX 2011011220 A MX2011011220 A MX 2011011220A MX 2011011220 A MX2011011220 A MX 2011011220A MX 344222 B MX344222 B MX 344222B
- Authority
- MX
- Mexico
- Prior art keywords
- naproxen
- naproxene
- new formulation
- compositions
- particles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17228909P | 2009-04-24 | 2009-04-24 | |
| AU2009901746A AU2009901746A0 (en) | 2009-04-24 | A Novel Formulation of Naproxen | |
| PCT/AU2010/000470 WO2010121326A1 (en) | 2009-04-24 | 2010-04-23 | A novel formulation of naproxen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2011011220A MX2011011220A (es) | 2012-02-08 |
| MX344222B true MX344222B (es) | 2016-12-07 |
Family
ID=43010609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011011220A MX344222B (es) | 2009-04-24 | 2010-04-23 | Una formulacion novedosa de naproxeno. |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US20120148634A1 (enExample) |
| EP (1) | EP2421512A4 (enExample) |
| JP (2) | JP6116244B2 (enExample) |
| KR (3) | KR20160135370A (enExample) |
| CN (2) | CN102438592B (enExample) |
| AP (1) | AP3530A (enExample) |
| AU (1) | AU2010239085C1 (enExample) |
| CA (1) | CA2759122A1 (enExample) |
| CO (1) | CO6470806A2 (enExample) |
| EA (1) | EA201171284A1 (enExample) |
| IL (1) | IL215868A0 (enExample) |
| MA (1) | MA33299B1 (enExample) |
| MX (1) | MX344222B (enExample) |
| NZ (2) | NZ595985A (enExample) |
| SG (2) | SG175767A1 (enExample) |
| TN (1) | TN2011000536A1 (enExample) |
| UA (1) | UA111578C2 (enExample) |
| WO (1) | WO2010121326A1 (enExample) |
| ZA (1) | ZA201108648B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2054042B8 (en) | 2006-06-30 | 2020-06-10 | iCeutica Pty Ltd | Methods for the preparation of biologically active compounds in nanoparticulate form |
| MY159208A (en) | 2009-04-24 | 2016-12-30 | Iceutica Pty Ltd | A novel formulation of indomethacin |
| SG10201607849TA (en) * | 2009-04-24 | 2016-11-29 | Iceutica Pty Ltd | Production of encapsulated nanoparticles at commercial scale |
| KR101794032B1 (ko) * | 2011-09-21 | 2017-11-07 | (주)바이오시네틱스 | 나노입자 제조방법 |
| WO2015179098A1 (en) | 2014-05-21 | 2015-11-26 | Integenx Inc. | Fluidic cartridge with valve mechanism |
| US9526734B2 (en) | 2014-06-09 | 2016-12-27 | Iceutica Pty Ltd. | Formulation of meloxicam |
| US11175268B2 (en) | 2014-06-09 | 2021-11-16 | Biometry Inc. | Mini point of care gas chromatographic test strip and method to measure analytes |
| US11435340B2 (en) | 2014-06-09 | 2022-09-06 | Biometry Inc. | Low cost test strip and method to measure analyte |
| GB201506755D0 (en) | 2015-04-21 | 2015-06-03 | Reckitt Benckiser Llc | Novel pharmaceutical formulation |
| US10210410B2 (en) | 2014-10-22 | 2019-02-19 | Integenx Inc. | Systems and methods for biometric data collections |
| US10690627B2 (en) | 2014-10-22 | 2020-06-23 | IntegenX, Inc. | Systems and methods for sample preparation, processing and analysis |
| CA3001337C (en) | 2015-10-09 | 2023-12-12 | Reckitt Benckiser Llc | Pharmaceutical formulation |
| DK3411031T3 (da) | 2016-02-04 | 2024-10-21 | Cindome Pharma Inc | Deutererede domperidonpræparater og fremgangsmåder til terapi af lidelser |
| JP7086927B2 (ja) | 2016-07-19 | 2022-06-20 | バイオメトリー・インコーポレイテッド | バッチ校正可能なテストストリップを用いる検体測定方法と検体測定システム |
| JP7163015B2 (ja) * | 2016-10-31 | 2022-10-31 | エスエス製薬株式会社 | 経口固形組成物 |
| EP3613415B1 (en) * | 2017-04-21 | 2022-11-09 | Bio-Synectics Inc. | Method for preparing active material nanoparticles using lipid as lubricant for milling |
| KR20240125702A (ko) | 2017-06-30 | 2024-08-19 | 신돔 파마, 인크. | 중수소화 돔페리돈 조성물, 방법, 및 제조 |
| US12478612B2 (en) | 2017-06-30 | 2025-11-25 | Cindome Pharma, Inc. | Deuterated domperidone compositions, methods, and preparation |
| US11779541B2 (en) * | 2019-03-26 | 2023-10-10 | Johnson & Johnson Consumer Inc. | Immediate release dosage form |
| TW202241409A (zh) * | 2020-12-18 | 2022-11-01 | 南韓商大熊製藥股份有限公司 | 包含1-(5-(2,4-二氟苯基)-1-((3-氟苯基)磺醯基)-4-甲氧基-1h-吡咯-3-基)-n-甲基甲胺之用於經口投予的新調配物 |
| KR20250112022A (ko) * | 2024-01-16 | 2025-07-23 | 피투케이바이오 주식회사 | 리바록사반 흡입용 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2642486B2 (ja) * | 1989-08-04 | 1997-08-20 | 田辺製薬株式会社 | 難溶性薬物の超微粒子化法 |
| WO1998035666A1 (en) * | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
| US20030087308A1 (en) * | 2001-06-22 | 2003-05-08 | Elan Pharma International Limited | Method for high through put screening using a small scale mill or microfluidics |
| CA2858733C (en) * | 2004-12-31 | 2017-12-19 | Iceutica Pty Ltd | Nanoparticle compositions and methods for synthesis thereof |
| EP2054042B8 (en) * | 2006-06-30 | 2020-06-10 | iCeutica Pty Ltd | Methods for the preparation of biologically active compounds in nanoparticulate form |
| US20100003332A1 (en) * | 2006-07-27 | 2010-01-07 | Amorepacific Corporation | Process For Preparing Powder Comprising Nanoparticles of Sparingly Soluble Drug |
| SG10201607849TA (en) * | 2009-04-24 | 2016-11-29 | Iceutica Pty Ltd | Production of encapsulated nanoparticles at commercial scale |
| EA201171282A1 (ru) * | 2009-04-24 | 2012-05-30 | Айсьютика Пти Лтд. | Способ производства коммерческих порошков, содержащих нано- и микрочастицы |
| WO2010121321A1 (en) * | 2009-04-24 | 2010-10-28 | Iceutica Pty Ltd | Method for improving the dissolution profile of a biologically active material |
| KR20150032759A (ko) * | 2009-04-24 | 2015-03-27 | 아이슈티카 피티와이 리미티드 | 큰 용적 분율로 캅셀화된 나노입자의 생산 |
-
2010
- 2010-04-23 UA UAA201113810A patent/UA111578C2/uk unknown
- 2010-04-23 AP AP2011005991A patent/AP3530A/xx active
- 2010-04-23 EA EA201171284A patent/EA201171284A1/ru unknown
- 2010-04-23 CA CA2759122A patent/CA2759122A1/en not_active Abandoned
- 2010-04-23 SG SG2011077476A patent/SG175767A1/en unknown
- 2010-04-23 CN CN201080017987.8A patent/CN102438592B/zh not_active Expired - Fee Related
- 2010-04-23 KR KR1020167032025A patent/KR20160135370A/ko not_active Ceased
- 2010-04-23 US US13/266,119 patent/US20120148634A1/en not_active Abandoned
- 2010-04-23 WO PCT/AU2010/000470 patent/WO2010121326A1/en not_active Ceased
- 2010-04-23 EP EP10766519A patent/EP2421512A4/en not_active Withdrawn
- 2010-04-23 MX MX2011011220A patent/MX344222B/es active IP Right Grant
- 2010-04-23 MA MA34386A patent/MA33299B1/fr unknown
- 2010-04-23 NZ NZ595985A patent/NZ595985A/en not_active IP Right Cessation
- 2010-04-23 CN CN201410119438.1A patent/CN103877030A/zh active Pending
- 2010-04-23 AU AU2010239085A patent/AU2010239085C1/en not_active Ceased
- 2010-04-23 KR KR1020147034848A patent/KR20150008909A/ko not_active Ceased
- 2010-04-23 SG SG10201401720RA patent/SG10201401720RA/en unknown
- 2010-04-23 KR KR1020117027887A patent/KR20120104489A/ko not_active Ceased
- 2010-04-23 JP JP2012506288A patent/JP6116244B2/ja active Active
- 2010-04-23 NZ NZ626401A patent/NZ626401A/en not_active IP Right Cessation
-
2011
- 2011-10-23 IL IL215868A patent/IL215868A0/en unknown
- 2011-10-24 TN TNP2011000536A patent/TN2011000536A1/en unknown
- 2011-11-23 CO CO11160580A patent/CO6470806A2/es not_active Application Discontinuation
- 2011-11-24 ZA ZA2011/08648A patent/ZA201108648B/en unknown
-
2014
- 2014-01-21 US US14/160,463 patent/US20140200276A1/en not_active Abandoned
- 2014-11-24 US US14/552,413 patent/US20150087709A1/en not_active Abandoned
-
2015
- 2015-05-20 JP JP2015102945A patent/JP6177275B2/ja not_active Expired - Fee Related
- 2015-07-14 US US14/799,438 patent/US20150313857A1/en not_active Abandoned
-
2016
- 2016-04-07 US US15/093,667 patent/US20160220518A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011011220A (es) | Una formulacion novedosa de naproxeno. | |
| CO6470810A2 (es) | Una formulación novedosa de diclofenaco | |
| CO6470807A2 (es) | Una formulacion novedosa de indometacina | |
| CO6470803A2 (es) | Una formulacion novedosa de meloxicam | |
| MX2011011218A (es) | Produccion de nanoparticulas encapsuladas a escala comercial. | |
| CO6470805A2 (es) | Producción de monopartículas encapsuladas en fracciones de alto volumen | |
| CR20150326A (es) | Inhibidores de autotaxina | |
| GT201400016A (es) | Indazoles | |
| PE20150631A1 (es) | Formas cristalinas de un modulador del receptor androgenico | |
| SV2011003855A (es) | Heteroarilos sustituidos | |
| CL2013001947A1 (es) | Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona. | |
| HN2010002518A (es) | Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina | |
| GT201200284A (es) | Composición farmacéutica | |
| DOP2009000287A (es) | Oxazolidinonas sustituidas y su uso | |
| PH12014501967A1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
| PE20140255A1 (es) | Tableta dispersable en forma oral | |
| BRPI1014278B8 (pt) | método para produzir uma forma de dosagem compreendendo metaxolona, forma de dosagem, composição farmacêutica compreendendo a referida forma de dosagem e uso da mesma | |
| CL2015001610A1 (es) | Compuestos derivados de pirimido-[4,5-b]-quinolina-4,5(3h,10h)-dionas para utilizarse como un medicamento para el tratamiento de una enfermedad causada por una mutacion sin sentido; composicion y combinacion farmaceutica que los comprende. | |
| GT201500035A (es) | Composición farmacéutica oral en forma de microesferas y proceso de elaboración | |
| ECSP14027694A (es) | Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido | |
| DOP2009000285A (es) | (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulacion sanguinea. | |
| MX2016000294A (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
| BR112014030992A2 (pt) | composições compreendendo calcogenetos e métodos relacionados | |
| BRPI1015538A2 (pt) | nova formulação de naproxeno | |
| AU2014208310B2 (en) | A Novel Formulation of Diclofenac |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |